MD, PhD, MRCPsych, Clinical Senior Lecturer in General Psychiatry in Centres for Neuropsychopharmacology and Psychedelic Research at Imperial and Consultant Psychiatrist at St Charles Hospital, CNWL Mental Health NHS Foundation Trust. From early 2021 heading a new NHS-based research clinic at St Charles Hospital, the CIPPRes Clinic.
David conducts psychopharmacological research, using brain-imaging techniques such as PET and MRI. He was trained in PET imaging at Columbia University in New York and later undertook a PhD at University Hospital Rigshospitalet in Copenhagen. Since 2009 he has been involved in post-doc imaging research into the neurobiology of addictions and major depression at Imperial. David has been investigating dopaminergic neurotransmission with measurements of the dopamine D3 receptor in alcohol addiction, studies of opioid neurotransmission in pathological gambling, and functional imaging studies looking at the role of dopamine D3 and mu-opiate receptors in cocaine, alcohol, and heroin addiction.
Currently, he runs lab-based multi-modal brain imaging studies [often using pharmacological challenges] focusing on serotonin/dopamine/opiate neurotransmission as well as larger-scale prospective, naturalistic studies with online assessments and/or field-based data collection. Specifically, in the Centre for Psychedelic Research [where David is Clinical Director and Deputy Head], the team is investigating brain mechanisms and therapeutic potential of MDMA, ketamine and classic psychedelics.
et al., 2022, Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample., J Psychopharmacol, Vol:36, Pages:932-942
et al., 2021, Psychedelics and health behaviour change, Journal of Psychopharmacology, Vol:36, ISSN:0269-8811, Pages:12-19
et al., 2021, Can pragmatic research, real-world data and digital technologies aid the development of psychedelic medicine?, Journal of Psychopharmacology, Vol:36, ISSN:0269-8811, Pages:6-11
et al., 2020, Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies, Acta Psychiatrica Scandinavica, Vol:143, ISSN:0001-690X, Pages:101-118
et al., 2020, Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans, Journal of Psychopharmacology, Vol:35, ISSN:0269-8811, Pages:459-468